Search Patents
  • 1-arylethyl-3-substituted piperidines
    Patent number: 5410046
    Abstract: Synthetic intermediates of 1-arylethyl-3-substituted piperidines.
    Type: Grant
    Filed: May 11, 1993
    Date of Patent: April 25, 1995
    Assignee: Pfizer Inc.
    Inventors: David Alker, Peter E. Cross, Robert M. Wallis
  • Pharmaceutical composition for the treatment of CNS and other disorders
    Patent number: 6881734
    Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant ?7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant ?7 nicotinic receptor agonist.
    Type: Grant
    Filed: April 27, 2004
    Date of Patent: April 19, 2005
    Assignee: Pfizer Inc.
    Inventors: Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher J. O'Donnell
  • Quinazoline-4-one AMPA antagonists
    Patent number: 6060479
    Abstract: The present invention relates to novel quinazolin-4-one derivatives of the formula I, as defined in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurodegenerative, psychotropic, and drug and alcohol induced central and peripheral nervous system disorders.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: May 9, 2000
    Assignee: Pfizer Inc
    Inventors: Bertrand L. Chenard, Willard M. Welch
  • Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same
    Publication number: 20200261596
    Abstract: Disclosed herein are compositions for treating and preventing diseases such as myeloma and lymphoma, where the compositions include a biocompatible, therapeutic polymeric nanoparticle having a boronate ester compound or a peptide boronic acid compound, and a biodegradable polymer. Methods of use of the therapeutic compositions are also disclosed.
    Type: Application
    Filed: October 19, 2017
    Publication date: August 20, 2020
    Applicant: Pfizer Inc.
    Inventors: Mir Mukkaram Ali, Maria Conceicao Figueiredo, Jeffrey Hrkach, Young-Ho Song, James Wright, Stephen E. Zale
  • Substituted arylpyrazoles
    Patent number: 7645786
    Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: January 12, 2010
    Assignee: Pfizer Inc.
    Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
  • Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents
    Patent number: 5543411
    Abstract: This invention relates to the use of certain hydroxylated metabolites and derivatives of doxazosin and their pharmaceutically acceptable acid addition salts for retarding the development of atherosclerosis in a mammal. Such compounds are useful for reducing atherosclerotic plaque involvement and for retarding and reducing both lipid deposition fibrosis in the development of atherosclerotic plaques.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: August 6, 1996
    Assignee: Pfizer Inc.
    Inventors: Archie C. Swindell, Samuel S. Wong
  • CANCER TREATMENT
    Publication number: 20190331687
    Abstract: Diagnostic methods for predicting whether a human tumor is sensitive to treatment with axitinib, and methods of treating a human tumor are disclosed. The methods are based on measurement of CD68 polypeptide expression levels in a tissue sample from a tumor. CD68 expression levels can be measured using immunohistochemistry, where the percentage of CD68-positive cells and density of CD68-positive cells within the tumor can be determined.
    Type: Application
    Filed: March 1, 2019
    Publication date: October 31, 2019
    Applicant: PFIZER INC.
    Inventors: Jean-François André MARTINI, Jamal Christo TARAZI, James Andrew WILLIAMS
  • Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
    Patent number: 9370516
    Abstract: The present invention relates to methods of treating sleep disorders in patients comprising administration of a ghrelin receptor inverse agonist or antagonist. The invention also includes methods of treating sleep disorders comprising the administration of a pharmaceutical composition comprising a ghrelin receptor inverse agonist or antagonist and at least one pharmaceutically acceptable carrier, diluent, or excipient.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: June 21, 2016
    Assignee: Pfizer Inc.
    Inventors: William S. Denney, Margaret Jackson, Gabriele Sonnenberg
  • 5-(2-Carboxythiophen-5-y l)-16-aryloxy-.alpha.-tetranor-.omega.-tetranorprostaglandins
    Patent number: 4065472
    Abstract: 5-(2-Carboxythiophen-5-yl)-16-aryloxy-.alpha.-tetranor-.omega.-tetranorpros taglandins and intermediates useful in their preparation are disclosed. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins but they exhibit a greater tissue specificity of action.
    Type: Grant
    Filed: September 29, 1975
    Date of Patent: December 27, 1977
    Assignee: Pfizer Inc.
    Inventors: Thomas K. Schaaf, Jasjit Singh Bindra
  • Protogyny in Zea mays
    Patent number: 4677246
    Abstract: Novel protogynous Zea mays plants are disclosed, including a novel protogynous inbred line, LALGI. Also disclosed are a process to produce such Zea mays plants and hybrids resulting from crossing such plants with other inbred lines such as Iowa Stiff Stalk Synthetic Lines.
    Type: Grant
    Filed: April 26, 1985
    Date of Patent: June 30, 1987
    Assignee: Dekalb-Pfizer Genetics
    Inventors: Paul A. Armond, Peter M. Orr
  • Crystalline Forms of Cis-5-Fluoro-N-[4-(2-Hydroxy-4-Methylbenzamido) Cyclohexyl]-2-(Tetrahydrothiopyran-4-Yloxy) Nicotinamide
    Publication number: 20080194635
    Abstract: The present invention relates to new crystalline forms of syn-5-Fluoro-N-[4-(2-hydroxy-4-methyl-benzoylamino)-cyclohexyl ]-2-(tetrahydro-thiopyran-4-yloxy)-nicotinamide and to processes for the preparation of, compositions containing and the uses of such crystalline forms.
    Type: Application
    Filed: January 11, 2006
    Publication date: August 14, 2008
    Applicant: PFIZER INC.
    Inventors: Lorraine Michelle Murtagh, Stefan Colin John Taylor, Niamph Josephine Willis
  • Antiviral Heteroaryl Ketone Derivatives
    Publication number: 20230339930
    Abstract: The invention relates to compounds of Formula I wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
    Type: Application
    Filed: July 7, 2021
    Publication date: October 26, 2023
    Applicant: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Martin Youngjin Pettersson, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Qingyi Yang
  • Diagnostic Anti-PD-L1 Antibody and Use Thereof
    Publication number: 20190211104
    Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.
    Type: Application
    Filed: September 20, 2017
    Publication date: July 11, 2019
    Applicants: Merck Patent GmbH, Pfizer Inc.
    Inventors: Claudia WILM, Klaus SCHNEIDER, Heike DAHMEN
  • Mutant porcine reproductive and respiratory syndrome virus
    Patent number: 7879337
    Abstract: The present invention provides a genetically modified PRRS virus which has been modified such that the conserved cysteine in the E protein has been deleted or changed to a non-cysteine residue and polynucleotides that encode it. Vaccines comprising the genetically modified virus and polynucleotides are also provided.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: February 1, 2011
    Assignee: Pfizer Inc.
    Inventors: Dongwan Yoo, Changhee Lee, Jay Gregory Calvert
  • ANTIPARASITIC AGENTS
    Publication number: 20100010093
    Abstract: The present invention relates to compounds of the formula (I) or a tautomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, tautomer or prodrug, wherein: R1, R2, R3, R4 and R5 are each independently selected from H, halo, CN, CF3 and CONH2; compositions containing such compounds and the uses of such compounds as antiparasitic agents.
    Type: Application
    Filed: September 15, 2009
    Publication date: January 14, 2010
    Applicant: PFIZER LIMITED
    Inventors: Stuart Nicholas Comlay, Joanne Clare Hannam, William Howson, Christelle Lauret, Yogesh Anil Sabnis
  • Alkylmercaptomethylquinoxaline-1,4-dioxides and oxidized derivatives thereof
    Patent number: 3931174
    Abstract: Novel quinoxaline-1,4-dioxides of the formula ##SPC1##Wherein R is hydrogen or methyl;Y is lower alkyl; andn is 0, 1, or 2;Methods for their preparation; and their use as antibacterial agents and agents for promoting growth and improving feed efficiency of animals. Additionally, those compounds wherein n is 0 or 1 serve as intermediates for preparation of compounds wherein n is 1 or 2.
    Type: Grant
    Filed: January 23, 1974
    Date of Patent: January 6, 1976
    Assignee: Pfizer Inc.
    Inventor: James W. McFarland
  • Pyrazole compounds as transforming growth factor (TGF) inhibitors
    Patent number: 6958354
    Abstract: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: October 25, 2005
    Assignee: Pfizer Inc.
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Browning composition and process for browning foods
    Patent number: 5139800
    Abstract: There is disclosed a browning composition for uncooked foods comprising a colorant and a fat or an oil. Also disclosed is a process for imparting a brown color to cooked foods by using the composition of the present invention on foods cooked, for example, in a microwave oven.
    Type: Grant
    Filed: November 2, 1990
    Date of Patent: August 18, 1992
    Assignee: Pfizer Inc
    Inventors: James M. Anderson, Ping W. Chang, Christopher A. Macri, James W. Miller, Divina V. Sarges
  • Immunogenic compositions for use in pneumococcal vaccines
    Patent number: 11135279
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 5, 2021
    Assignee: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Cobalt-chromium superalloy
    Patent number: 4631082
    Abstract: An oxide dispersion strengthened cobalt-chromium superalloy produced by mechanical alloying containing a refractory oxide, preferably yttrium oxide, and characterized by excellent corrosion resistance, high fatigue strength and high temperature stability; and prostheses formed from said superalloy.
    Type: Grant
    Filed: February 20, 1985
    Date of Patent: December 23, 1986
    Assignee: Pfizer Hospital Products Group Inc.
    Inventors: Henry L. Andrews, Gregory E. Gardiner
Narrow Results

Filter by US Classification